NTAX-44 : Out Licencing Opportunity

Novel Oral Nano Arsenic complex for Hematological Malignancies and Solid Tumors.

Arsenic has a tremendous anticancer potential which is evident from the fact that there are currently over 100 clinical trials going on in various parts of globe as a mono-therapy as well as in combination with other Biological & Chemical Agents for the treatment of hematologic and solid tumor malignancies.
Arsenic has well known history of toxicity and current treatments with arsenic have several limitations in terms of the therapy related side effects.
RBPL successfully removed the dose related toxicity in Arsenic with a unique patented green process keeping its therapeutic properties intact.

Successfully completed Pilot Clinical trial (AYUSH) “A prospective, open label, pilot study to evaluate safety, efficacy and bio- availability of oral Arsenic compound (Somal, NTAX-44 an arsenic based compound) in patients with solid tumors”.
Currently, under process of Ph II/III submission to DCGI for Glioblastoma (GBM) patients.
Also, planning for BA/BE studies for Acute Promyelocytic Leukemia (APML).

RBPL is currently exploring opportunities for financial / strategic partnerships with companies having global reach for the above product.

RBPL has developed an oral arsenic drug which has potential to overcome the shortcomings of the intravenous arsenic drug. NTAX-44 is designed for slow absorption and slow release while maintaining prolonged systemic availability for intended therapeutic benefit
The invitro data suggests that NTAX-44 reduces the percent viability in a panel of human cancer cell lines and demonstrated significant anti-angiogenic potential in-ovo chick embryo yolk sac membrane model
NTAX-44 is bioavailable when administered orally, and it has demonstrated good safety and tolerability at 12 mg dose level in bioavailability clinical trials
These studies are indicative of the potential role of NTAX-44 as an oral chemotherapeutic agent in the treatment of Pancreatic cancer